Experimental CAR-T therapy tested in one patient for Hard-to-Treat myeloma
NCT ID NCT06068400
First seen Mar 27, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study tested a new CAR-T cell therapy in one person with multiple myeloma that had come back or stopped responding to other treatments. The goal was to see if the treatment was safe and could shrink the cancer. The study was stopped early, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shenzhen Qianhai Shekou Free Trade Zone Hospital
Shenzhen, Guangdong, 518000, China
Conditions
Explore the condition pages connected to this study.